Get started
Evolus, Inc. Common StockEvolus, Inc. Common StockEvolus, Inc. Common Stock

Evolus, Inc. Common Stock

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Trade ideas

Eols. Closing the gap.The company recently exceeded revenue estimates for the quarter. Despite market turbulence, the price is holding up well. Short float is 22%. Temporary undervaluation. The current price is far from its 52-week high, which means there is room for recovery. Analyst consensus and targets. Some recent reviews give a target in the $18 range, which is significantly higher than the current ~$7. This creates a "vacuum" in price expectations, which provides an opportunity for growth. The company usually shows growth from November to March.
NASDAQ:EOLSLong
by ati1981
BUY TODAY SELL TOMORROW for 5%DON’T HAVE TIME TO MANAGE YOUR TRADES? - Take BTST trades at 3:25 pm every day - Try to exit by taking 4-7% profit of each trade - SL can also be maintained as closing below the low of the breakout candle Now, why do I prefer BTST over swing trades? The primary reason is that I have observed that 90% of the stocks give most of the movement in just 1-2 days and the rest of the time they either consolidate or fall Trendline Breakout in EOLS BUY TODAY SELL TOMORROW for 5%
NASDAQ:EOLS
by Kapil-Mittal
2
Spotting Opportunity in Retracement - Long Trade Idea Greetings, fellow traders! Today, I present an intriguing long trade idea for EOLS stock, focusing on a potential retracement opportunity. Through careful analysis, we anticipate a retracement to the key level of $7.59, where we plan to enter the market . Our stop loss is set at $7.12 , and we have identified a profit target of $14.33 , offering an exceptional risk-reward ratio of approximately 1 to 14.34 . The rationale behind this trade idea is based on our analysis of INTC's price action, suggesting a potential retracement to volume imbalance. By strategically positioning our entry at $7.59, we aim to capitalize on the upward momentum that may emerge from this retracement. To manage risk effectively, we have placed our stop loss at $7.12. This level provides a buffer below our entry point, helping to limit potential losses in case of adverse price movements. Additionally, we have identified a profit target of $14.33, considering it as a key resistance level that could be reached during a potential uptrend. The impressive risk-reward ratio of approximately 1 to 14.34 underscores the compelling nature of this trade. It is important to note that trading involves risks, and this idea is shared for educational purposes only. We encourage you to conduct your own analysis, consider your risk tolerance, and, if needed, seek advice from qualified professionals before making any trading decisions. TRADING as a BUSINESS wishing you success as you navigate the potential retracement opportunity presented by INTC stock. Remember to stay disciplined, manage risk wisely, and adapt your strategy to evolving market conditions. Disclaimer: The provided trade idea is for educational purposes only and should not be considered as financial advice. Trade at your own risk, and exercise caution in your decision-making process.
NASDAQ:EOLSLong
by trading_as_bus
1
$EOLS skyrocketed after end of Intellectual Property LitigationAbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be dismissed. Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox's trade secrets and grant a license to Evolus to continue to commercialize Jeuveau® in the United States and Nuceiva™ in all other territories in which Evolus has licensing rights. AbbVie and Medytox will receive milestone and royalty payments from Evolus. In addition, Evolus will issue common stock to Medytox. finance.yahoo.com
NASDAQ:EOLS
by AlenCiken
EOLS Bear DivergenceHello, What is EOLS? Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. News My Thoughts For You We were overbought with a bearish divergence and most likely we will see this play out as indicated on the chart. Good Luck, Cheers! Be sure to comment, follow, like, and check out my profile for more trade ideas!
NASDAQ:EOLSShort
by keifer
1